Figure 3From: Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trialsDose reduction, dose delay, hospitalization, therapy discontinuation, and death versus schedule. (a) For all patients. (b) For patients younger than 60 years old. (c) For patients aged 60 to 64 years. (d) For patients older than 64 years of age.Back to article page